US Pharma MarketingWith Elahere building steam, AbbVie nets FDA nod for another ImmunoGen cancer asset
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate (ADC) Elahere, another of the acquired company’s clinical assets has crossed the FD As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards Outsourcing Awards Innovation Awards Pharma…
As AbbVie continues to capitalize on its deal for ImmunoGen with the growth of commercial antibody-drug conjugate Elahere, another of the acquired company’s clinical assets has crossed the FDA finish line.
Source: FiercePharma